NCT05871762 Choice of the Optimal Treatment Strategies for Mid-low REctal Cancer
| NCT ID | NCT05871762 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking Union Medical College Hospital |
| Condition | Rectal Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,705 participants |
| Start Date | 2023-06-04 |
| Primary Completion | 2027-05-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,705 participants in total. It began in 2023-06-04 with a primary completion date of 2027-05-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to compare the efficacy, prognosis, health economics of different treatment modalities of mid-low rectal cancer in different centers in China, and to conduct cost utility analysis (CUA) on the treatment process of rectal cancer to explore the best treatment modality that meets the actual need of medical units in each region and at each level. The investigators hope to provide evidence-based medical suggestions for medical quality control of rectal cancer and revision of clinical guidelines, and provides a source of decision making for medical management and medical insurance.
Eligibility Criteria
Inclusion Criteria: * pathologically confirmed rectal adenocarcinoma * located within 12cm below the anal verge Exclusion Criteria: * diagnosed with distant metastasis * multiple primary colorectal cancers * history of previous malignant tumors * Pregnant or lactating women
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05871762 clinical trial?
This trial is open to participants of all sexes, studying Rectal Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05871762 currently recruiting?
Yes, NCT05871762 is actively recruiting participants. Contact the research team at Xiaoy@pumch.cn for enrollment information.
Where is the NCT05871762 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT05871762 clinical trial?
NCT05871762 is sponsored by Peking Union Medical College Hospital. The trial plans to enroll 3,705 participants.